AavantiBio Revenue and Competitors

Boston, MA USA

Location

$107M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • AavantiBio's estimated annual revenue is currently $852.5k per year.(i)
  • AavantiBio's estimated revenue per employee is $77,500
  • AavantiBio's total funding is $107M.

Employee Data

  • AavantiBio has 11 Employees.(i)
  • AavantiBio grew their employee count by -45% last year.

AavantiBio's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$570.5M248312%$219M$3.1B
Add Company

What Is AavantiBio?

AavantiBio is a clinical-stage biopharmaceutical company committed to developing and commercializing novel gene transfer and gene editing therapies for the treatment of rare and ultra-rare genetic diseases. The company is rapidly building a diverse portfolio of gene transfer and gene editing therapies to target debilitating genetic diseases for which the unmet medical need is high for which there are typically no approved therapies treating the underlying disease. AavantiBio is headquartered in Cambridge, MA with additional locations in Gainesville, FL. We are looking for exceptional individuals who share our passion for developing novel therapies to treat rare diseases and advancing the field of gene transfer therapy. Developing genetic treatments for rare diseases is inspiring but challenging work and it takes dedication and courage which will make a meaningful impact on those who suffer from rare diseases. At AavantiBio, we will push each other to perform at our very best, and build a company that not only our employees are proud of, but also the rare disease community, because everyone knows we are trying to make a difference in patients' lives. Come join our team!

keywords:N/A

$107M

Total Funding

11

Number of Employees

$852.5k

Revenue (est)

-45%

Employee Growth %

N/A

Valuation

N/A

Accelerator

AavantiBio News

2022-04-17 - Global Frataxin Mitochondrial Market Incredible Possibilities ...

AavantiBio Inc; Adverum Biotechnologies Inc; Anima Biotech Inc; Biointaxis SL; Cellivery Therapeutics Inc; CRISPR Therapeutics AG; Design...

2021-04-27 - AavantiBio and Catalent Announce Partnership to Support Development and Manufacturing of Gene Therapies for Rare Genetic Diseases

Our development team at the University of Maryland BioPark is focused on providing process optimization services to meet our customers’ needs and partnering with them to bring innovative therapies to patients faster CAMBRIDGE, Mass. and SOMERSET, N.J. (PRWEB) April 27, 2021 AavantiBio, a gene ...

2020-10-22 - AavantiBio Launches with $107M in Series A Financing

AavantiBio, a Cambridge, MA-based gene therapy company, launched with $107M in Series A financing. A premier syndicate of life sciences investors including Perceptive Advisors, Bain Capital Life Sciences, and RA Capital Management together with Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a leade ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1M11N/AN/A
#2
$1.8M11N/AN/A
#3
$3.5M11-31%$116.2M
#4
$2.9M110%N/A
#5
$1M1110%N/A